Autocrine prolactin: An emerging market for homegrown (prolactin) despite the imports

Genes and Development

Volumn 26, Issue 20, 2012, Pages 2253-2258

  Muthuswamy, Senthil K ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Simons Center for Quantitative Biology   (United States)

Author keywords

Akt; Differentiation; Lactation; Mammary gland; Pten; Stat5

Indexed keywords

CYCLIN D1; GLUTATHIONE TRANSFERASE; MESSENGER RNA; PROLACTIN; PROLACTIN RECEPTOR; PROTEIN BCL 2; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER GROWTH; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPETITIVE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION; LACTATION; PREGNANCY; PROLACTIN; PROTO-ONCOGENE PROTEINS C-AKT; STAT5 TRANSCRIPTION FACTOR;

EID: 84867709494     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.204636.112     Document Type: Article

References (60)

1. Acosta JJ. 2003. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Methods Enzymol 17: 2268-2282.
2. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA. 2006. Prolactin potentiates transforming growth factor a induction of mammary neoplasia in transgenic mice. Am J Pathol 168: 1365-1374.
3. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. 2011. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 13: R11. doi: 10.1186/bcr2819.
4. Beck MT, Peirce SK, Chen WY. 2002. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21: 5047-5055.
5. Ben-Jonathan N, Hnasko R. 2001. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22: 724-763.
6. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. 1996. Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects. Endocr Rev 17: 639-669.
7. Ben-Jonathan N, LaPensee CR, LaPensee EW. 2007. What can we learn from rodents about prolactin in humans? Endocr Rev 29: 1-41.
8. Biswas R, Vonderhaar BK. 1987. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in longterm tissue culture. Cancer Res 47: 3509-3514.
9. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. 1998. Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19: 225-268.
10. Boot LM, Ropcke G, Muhlbock O. 1962. Mammary tumour induction by pituitary isografts in mice. Acta Unio Int Contra Cancrum 18: 270-271.
11. Boyns AR, Buchan R, Cole EN, Forrest AP, Griffiths K. 1973. Basal prolactin blood levels in three strains of rat with differing incidence of 7,12-dimethylbenz(a)anthracene induced mammary tumours. Eur J Cancer 9: 169-171.
12. Brockman JL, Schuler LA. 2005. Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol 239: 45-53.
13. Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C. 1994. Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci 91: 5232-5236.
14. Chan CB, Liu X, Ensslin MA, Dillehay DL, Ormandy CJ, Sohn P, Serra R, Ye K. 2010. PIKE-A is required for prolactinmediated STAT5a activation in mammary gland development. EMBO J 29: 956-968.
15. Chen CC, Boxer RB, Stairs DB, Portocarrero CP, Horton RH, Alvarez JV, Birnbaum MJ, Chodosh LA. 2010. Akt is required for Stat5 activation and mammary differentiation. Breast Cancer Res 12: R72. doi: 10.1186/bcr2640.
16. Chen CC, Stairs DB, Boxer RB, Belka GK, Horseman ND, Alvarez JV, Chodosh LA. 2012. Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. Genes Dev 26: 2154-2168.
17. Clevenger CV. 2003. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 18: 75-86.
18. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. 1995. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146: 695-705.
19. DaSilva L, Howard OM, Rui H, Kirken RA, Farrar WL. 1994. Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem 269: 18267-18270.
20. David M, Petricoin EF 3rd, Igarashi K, Feldman GM, Finbloom DS, Larner AC. 1994. Prolactin activates the interferonregulated p91 transcription factor and the Jak2 kinase by tyrosine phosphorylation. Proc Natl Acad Sci 91: 7174-7178.
21. Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S. 1994. Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J 13: 2583-2591.
22. Frank SJ. 2002. Minireview: Receptor dimerization in GH and erythropoietin action-it takes two to tango, but how? Endocrinology 143: 2-10.
23. Gerlo S, Davis JRE, Mager DL, Kooijman R. 2006. Prolactin in man: A tale of two promoters. Bioessays 28: 1051-1055.
24. Ginsburg E, Vonderhaar BK. 1995. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55: 2591-2595.
25. Gouilleux F, Wakao H, Mundt M, Groner B. 1994. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13: 4361-4369.
26. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. 1999. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91: 629-634.
27. Harvey PW. 2011. Hypothesis Prolactin is tumorigenic to human breast: Dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J Appl Toxicol 32: 1-9.
28. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. 1997. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16: 6926-6935.
29. Huang Y, Li X, Jiang J, Frank SJ. 2006. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 25: 7565-7576.
30. Ingram DM, Nottage EM, Roberts AN. 1990. Prolactin and breast cancer risk. Med J Aust 153: 469-473.
31. Jahn GA, Edery M, Belair L, Kelly PA, Djiane J. 1991. Prolactin receptor gene expression in rat mammary gland and liver during pregnancy and lactation. Endocrinology 128: 2976-2984.
32. LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi EM, Afton SE, Ben-Jonathan N. 2009. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione- S-transferase. Carcinogenesis 30: 1298-1304.
33. Malarkey WB, Kennedy M, Allred LE, Milo G. 1983. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 56: 673-677.
34. Manhes C. 2006. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol 190: 271-285.
35. Maus MV, Reilly SC, Clevenger CV. 1999. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140: 5447-5450.
36. Meltzer HY, Fang VS. 1976. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33: 279-286.
37. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 136: 3619-3623.
38. Miller SL. 2005. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Methods Enzymol 19: 939-949.
39. Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV. 2007. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 26: 4668-4678.
40. Nagano M, Kelly PA. 1994. Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem 269: 13337-13345.
41. Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ. 2003. Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20: 111-114.
42. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner K-U, Kirken RA, Rui H. 2007. Coactivation of Janus Tyrosine Kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: Recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Methods Enzymol 21: 2218-2232.
43. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, et al. 1997. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11: 167-178.
44. Rider L, Diakonova M. 2011. Adapter protein SH2B1 binds filamin A to regulate prolactin-dependent cytoskeletal reorganization and cell motility. Methods Enzymol 25: 1231-1243.
45. Rider L, Shatrova A, Feener EP, Webb L, Diakonova M. 2007. JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and functions. J Biol Chem 282: 30985-30996.
46. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. 2003. Prolactin induces ERapositive and ERa-negative mammary cancer in transgenic mice. Oncogene 22: 4664-4674.
47. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. 1994. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 135: 1299-1306.
48. Sakamoto K, Creamer BA, Triplett AA, Wagner K-U. 2007. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Methods Enzymol 21: 1877-1892.
49. Schroeder MD, Symowicz J, Schuler LA. 2002. PRL modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16: 45-57.
50. Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. 2008. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 111: 241-250.
51. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. 2007. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25: 1482-1488.
52. Vonderhaar BK. 1989. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett 47: 105-110.
53. Vonderhaar BK. 1999. Prolactin involvement in breast cancer. Endocr Relat Cancer 6: 389-404.
54. Wakao H, Gouilleux F, Groner B. 1994. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13: 2182-2191.
55. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. 2002. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59: 1147-1154.
56. Welsch CW, Nagasawa H. 1977. Prolactin and murine mammary tumorigenesis: A review. Cancer Res 37: 951-963.
57. Welsch CW, Dombroske SE, McManus MJ, Calaf G. 1979. Effect of human, bovine and ovine prolactin on DNA synthesis by organ cultures of benign human breast tumours. Br J Cancer 40: 866-871.
58. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Törnell J. 1997. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100: 2744-2752.
59. Wieck A, Haddad P. 2002. Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324: 250-252.
60. Yamauchi T. 2000. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 275: 33937-33944.